Publication Name	World Journal of Ophthalmology
Manuscript ID	11648
Country	Israel

Received	2014-05-29 09:22
Peer-Review Started	2014-05-29 21:08
To Make the First Decision	2014-06-18 18:30
Return for Revision	2014-06-19 14:18
Revised	2014-07-05 02:56
Second Decision	2014-09-10 09:05
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2014-09-10 09:29
Articles in Press	2014-09-10 09:29
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2014-11-04 16:42
Publish the Manuscript Online	2014-11-14 13:11

ISSN	2218-6239 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Ophthalmology
Manuscript Type	Review
Article Title	What is new in central serous chorioretinopathy?
Manuscript Source	Invited Manuscript
All Author List	Michal Schaap-Fogler and Rita Ehrlich
Funding Agency and Grant Number
Corresponding Author	Michal Schaap-Fogler, MD, Department of Ophthalmology, Rabin Medical Center, Beilinson Campus, 39 Zabotinski Street, Petach Tikva 49100, Israel. fogler@gmail.com
Key Words	Central serous chorioretinopathy; Optical coherence tomography; Fundus autoflouresence; Multifocal electroretinography; Macular microperimetry
Core Tip	(1) New diagnostic tools and therapies may improve the prognosis of patients with chronic or recurrent central serous chorioretinopathy; (2) Changes in fundus autoflouresence images help differentiate an active disease from an inactive state; (3) Multifocal electroretinography and macular microperimetry may serve as follow up tools due to their ability to measure macular visual function; (4) Focal argon laser photocoagulation shortens disease duration but does not affect final prognosis; (5) Reduced-fluence photodynamic therapy improves visual acuity and resolves serous detachments; and (6) The role of anti-vascular endothelial growth factor agents, micropulse diode laser, corticosteroid antagonists, aspirin, anti-viral or Helicobacter pylori treatment is still being investigated.
Publish Date	2014-11-14 13:11
Citation	Schaap-Fogler M, Ehrlich R. What is new in central serous chorioretinopathy? World J Ophthalmol 2014; 4(4): 113-123
URL	http://www.wjgnet.com/2218-6239/full/v4/i4/113.htm
DOI	http://dx.doi.org/10.5318/wjo.v4.i4.113

Full Article (PDF)	WJO-4-113.pdf
Full Article (Word)	WJO-4-113.doc
Manuscript File	11648-Review.doc
Answering Reviewers	11648-Answering reviewers.pdf
Copyright License Agreement	11648-Copyright assignment.pdf
Peer-review Report	11648-Peer review(s).pdf
Scientific Misconduct Check	11648-CrossCheck.jpg
Scientific Editor Work List	11648-Scientific editor work list.pdf